Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some claims (notably the approved second-line indication after gemcitabine progression) are directionally consistent with the provided label excerpts. However, many other claims are unsupported because the supplied prescribing-information content does not substantiate the detailed formulation/design rationale, tumor concentration/systemic toxicity assertions, specific efficacy endpoints (progression-free and overall survival) at the level claimed, or the list of 'common side effects' and general monitoring statement. Several claims are potentially label-inconsistent or unverified given the limited label excerpts provided.
Category Scores
Accurate Statements
Onivyde is indicated for use in combination with other chemotherapy agents for patients with metastatic adenocarcinoma of the pancreas.
Supported in part by provided label excerpts describing combinations (NAPOLI-3 NALIRIFOX and NAPOLI-1 ONIVYDE/FU/LV) for metastatic pancreatic adenocarcinoma; specific approved regimen details beyond the excerpts cannot be fully verified.
Onivyde is typically used after treatment with gemcitabine-based therapy has progressed.
Supported by provided excerpt under ONIVYDE/FU/LV: 'for the treatment of patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.'
Unsupported Statements
Onivyde (nal-IRI) is an encapsulation of irinotecan hydrochloride in lipid-protein-bound nanoparticles.
The supplied label excerpts do not describe the formulation as 'lipid-protein-bound nanoparticles' or use the term 'encapsulation' in this specific manner.
Onivyde is typically used after treatment with gemcitabine-based therapy has progressed.
While the second-line indication is supported, 'typically used' implies general real-world sequencing beyond the label excerpt.
The nanoparticle formulation of Onivyde is designed to alter the distribution of irinotecan.
No supported formulation-mechanism/design rationale is present in the provided label excerpts.
The nanoparticle formulation of Onivyde is designed to increase the concentration of irinotecan in tumors.
No tumor concentration objective is supported by the provided label excerpts.
The nanoparticle formulation of Onivyde is designed to potentially reduce systemic toxicity.
No systemic-toxicity reduction rationale is supported by the provided label excerpts.
Clinical trials showed that Onivyde, when combined with specific chemotherapy regimens, can lead to improved progression-free survival for patients with advanced pancreatic cancer.
The supplied excerpts only provide safety/monitoring and dosage information; they do not substantiate PFS improvement claims.
Clinical trials showed that Onivyde, when combined with specific chemotherapy regimens, can lead to improved overall survival for patients with advanced pancreatic cancer.
The supplied excerpts only provide safety/monitoring and dosage information; they do not substantiate OS improvement claims.
Common side effects associated with Onivyde include diarrhea.
The excerpts describe severe/life-threatening diarrhea and withholding/management, but do not support a 'common side effects' frequency characterization or broad AE list.
Common side effects associated with Onivyde include fatigue.
No support for fatigue as a common side effect appears in the provided excerpts.
Common side effects associated with Onivyde include nausea.
No support for nausea as a common side effect appears in the provided excerpts.
Common side effects associated with Onivyde include vomiting.
No support for vomiting as a common side effect appears in the provided excerpts.
Common side effects associated with Onivyde include decreased appetite.
No support for decreased appetite as a common side effect appears in the provided excerpts.
Common side effects associated with Onivyde include stomatitis.
No support for stomatitis as a common side effect appears in the provided excerpts.
More serious side effects can occur with Onivyde treatment.
Directionally consistent with the presence of severe/life-threatening events in the excerpts, but the broad statement is not specifically supported as phrased (no general 'more serious side effects' statement in supplied text).
Patients are closely monitored by their healthcare providers during Onivyde treatment.
The excerpts do recommend monitoring CBC; however, the general 'closely monitored' characterization is broader than the specific monitoring language provided.
Contradictions
Important Omissions
Dose details for the two indicated combination settings (e.g., 50 mg/m2 q2 weeks with NALIRIFOX and 70 mg/m2 q2 weeks with ONIVYDE/FU/LV) are not included in the AI claims.
Importance:
Moderate
Specific safety management elements from label excerpts (CBC timing Days 1 and 8; exact withholding/resume criteria; diarrhea management with atropine/loperamide and withholding for Grade 2-4) are not reflected in the AI claims beyond a generic monitoring statement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims are either unsupported (general AE frequency list; mechanism/design rationale; efficacy endpoint improvements) or overbroad (general monitoring). While no direct contradictions were identified from the provided excerpts, the lack of label-specific safety instructions and reliance on unsupported generalizations could mislead users about risks and management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims (formulation design, tumor concentration/systemic toxicity rationale, OS/PFS benefits, and 'common side effects' list) are not supported by the provided prescribing-information excerpts; safety/monitoring claims are overly general and do not include label-specific guidance.
Suggested Improvement
Limit claims to what is explicitly supported by the provided label excerpts (e.g., the two combination indications after gemcitabine progression; severe neutropenia/diarrhea warnings; CBC monitoring timing; withholding criteria; and diarrhea avoidance with bowel obstruction). Remove unsupported formulation-mechanism and frequency-based AE lists unless supported by the actual label sections.